Tag: stage

AB “Ignitis grupė” (hereinafter – the Group) informs that on 4 July 2025, the Ministry of Finance of the Republic of Lithuania, which exercises the rights of the majority shareholder, announced the selection of six independent members of the Group’s Supervisory Board. This follows the upcoming end of the current Supervisory Board’s term of office on 25 October 2025. Candidates may apply until 24 July 2025 (inclusive).

AB “Ignitis grupė” (hereinafter – the Group) informs that on 4 July 2025, the Ministry of Finance of the Republic of Lithuania, which exercises the rights of the majority shareholder, announced the selection of six independent members of the Group’s Supervisory Board. This follows the upcoming end of the current Supervisory Board’s term of office on 25 October 2025. Candidates may apply until 24 July 2025 (inclusive).

– Honouring the Legacy of Toni Burnett with Leadership and Vision –

Tokyo, Japan and Cambridge, UK, 4 July 2025 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) today announces that it will receive US$4.8 million in milestone payments from Centessa Pharmaceuticals pursuant to its research collaboration with Centessa. The milestones were achieved as Centessa initiated clinical development of ORX142, its second novel orexin receptor 2 (OX2R) agonist, following the recent clearance of an Investigational New Drug (IND) application by the US Food and Drug Administration (FDA) for a Phase 1 clinical study of ORX142 in healthy volunteers. (click here).

Las Vegas, NV, July 03, 2025 (GLOBE NEWSWIRE) -- Area 52, a vanguard in cannabinoid science and botanical engineering, today announced the debut of its 2025 THCA Snow Caps collection, a groundbreaking line of premium hemp flower completely enveloped in pure THCA diamonds. Engineered to “Alienize Your Mind,” these crystalline-coated buds represent a new frontier in potency and sensory experience for the discerning cannabis connoisseur.

MONTREAL, July 03, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, today announced the Company will report financial results for its second quarter 2025 ended May 31 on Wednesday, July 9, 2025.

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, July 03, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that on July 1, 2025 (the “Grant Date”), ORIC granted a total of 9,000 non-qualified stock options and 1,600 restricted stock units to one new non-executive employee who began their employment with ORIC in June 2025.